Glut1 siRNA and shRNA Plasmids (h)

siRNA / miRNA gene silencing Human - HT-1376 GLUT1

Experiment
siRNA / miRNA gene silencing Human - HT-1376 GLUT1
Product
Glut1 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology
Manufacturer
Santa Cruz Biotechnology

Protocol tips

Protocol tips
Human bladder cancer cell lines UM-UC-3 and HT-1376 derived from high-grade transitional cell carcinoma (from the American Type Culture Collection, ATCC, Manassas, VA, USA) were cultured in Eagle's Minimum Essential Medium (EMEM; ATCC) supplemented with 10% (v/v) of fetal bovine serum (Life Technologies, Carlsbad, CA, USA), 100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 µg/mL amphotericin B (Sigma). GLUT1 was depleted in human bladder cancer cells using a pool of three target-specific 20–25 nt siRNA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). HT-1376 bladder cancer cells were transfected in 6- or 96-well culture plates, at 60–80% confluence, with GLUT1. Cells were also transfected with a scrambled siRNA in parallel as controls.For each transfection, cells were treated for 5 h with 2.4 µM of siRNA in transfection medium (Santa Cruz) containing 0.5 µL/cm2 of transfection reagent (Santa Cruz). After incubation, complete media was added and the cells were incubated for 24 or 48 h. GLUT1 downregulation was evaluated 24 h or 48 h post-transfection by Western blotting. The uptake and PDT experiments were performed 24 h or 48 h post-transfection with GLUT1 hsiRNA or galectin-1 hsiRNA, respectively.

Publication protocol

Human bladder cancer cell lines UM-UC-3 and HT-1376 derived from high-grade transitional cell carcinoma (from the American Type Culture Collection, ATCC, Manassas, VA, USA) were cultured in Eagle's Minimum Essential Medium (EMEM; ATCC) supplemented with 10% (v/v) of fetal bovine serum (Life Technologies, Carlsbad, CA, USA), 100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 µg/mL amphotericin B (Sigma). GLUT1 was depleted in human bladder cancer cells using a pool of three target-specific 20–25 nt siRNA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). HT-1376 bladder cancer cells were transfected in 6- or 96-well culture plates, at 60–80% confluence, with GLUT1. Cells were also transfected with a scrambled siRNA in parallel as controls.For each transfection, cells were treated for 5 h with 2.4 µM of siRNA in transfection medium (Santa Cruz) containing 0.5 µL/cm2 of transfection reagent (Santa Cruz). After incubation, complete media was added and the cells were incubated for 24 or 48 h. GLUT1 downregulation was evaluated 24 h or 48 h post-transfection by Western blotting. The uptake and PDT experiments were performed 24 h or 48 h post-transfection with GLUT1 hsiRNA or galectin-1 hsiRNA, respectively.

Full paper   Login or join for free to view the full paper.

Reviews

Glut1 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing siRNA / miRNA gene silencing Human - HT-1376 GLUT1 using Glut1 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology.

View full paper   Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Santa Cruz Biotechnology for Glut1 siRNA and shRNA Plasmids (h) below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing siRNA / miRNA gene silencing Human - HT-1376 GLUT1 using Glut1 siRNA and shRNA Plasmids (h) from Santa Cruz Biotechnology. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms